Arimitsu Y, Kmety E, Ananyina Y, Baranton G, Ferguson I R, Smythe L, Terpstra W J
Department of Bacteriology, National Institute of Health, Tokyo, Japan.
Bull World Health Organ. 1994;72(3):395-9.
We have developed a one-point microcapsule agglutination test (MCAT) for the serodiagnosis of leptospirosis. The MCAT kit was evaluated for use in humans by six WHO Collaborating Centres for Reference and Research on Leptospirosis. The laboratories classified their serum samples on the basis of the microscopic agglutination test (MAT) and the following screening tests: enzyme-linked immunosorbent assay (ELISA), macroscopic (slide) agglutination test, or the complement fixation test. The MCAT may in some instances give a positive result earlier in the course of the disease than MAT or the ELISA IgM; on the other hand, it did not detect antibodies against some serovars, for example, those of the Sejroe or Australis serogroup in Slovakia. In contrast, however, the MCAT detected antibodies to serovar hardjo (the same serogroup as Sejroe) in patients from the United Kingdom and the Russian Federation.
我们开发了一种用于钩端螺旋体病血清诊断的单点微胶囊凝集试验（MCAT）。六个世界卫生组织钩端螺旋体病参考和研究合作中心对MCAT试剂盒在人体中的应用进行了评估。这些实验室根据显微镜凝集试验（MAT）以及以下筛查试验对血清样本进行分类：酶联免疫吸附测定（ELISA）、宏观（玻片）凝集试验或补体结合试验。在某些情况下，MCAT可能比MAT或ELISA IgM在疾病过程中更早给出阳性结果；另一方面，它未能检测到针对某些血清型的抗体，例如斯洛伐克的 Sejroe 或 Australis 血清群的抗体。然而，相比之下，MCAT在来自英国和俄罗斯联邦的患者中检测到了针对hardjo血清型（与Sejroe同属一个血清群）的抗体。
